Startup Pheast Develops Next-Gen Immunotherapy

Pheast Therapeutics is pioneering a new immunotherapy approach by developing monoclonal antibodies that target the CD24 macrophage checkpoint. The company's lead candidate, PHST001, aims to activate macrophages against cancer and has received fast-track designation from regulators.